Lymphovascular invasion, whereby tumour cells or cell clusters are identified in the lumen of lymphatic or blood vessels, is thought to be an essential step in disease dissemination. It has been established as an independent negative prognostic indicator in a range of cancers. We therefore aimed to assess the impact of lymphovascular invasion at the time of prostatectomy on oncological outcomes. We performed a multicentre, retrospective cohort study of 3495 men who underwent radical prostatectomy for localised prostate cancer. Only men with negative preoperative staging were included. We assessed the relationship between lymphovascular invasion and adverse pathological features using multivariable logistic regression models. Kaplan-Meier curves and Cox proportional hazard models were created to evaluate the impact of lymphovascular invasion on oncological outcomes. Lymphovascular invasion was identified in 19% (n = 653) of men undergoing prostatectomy. There was an increased incidence of lymphovascular invasion-positive disease in men with high International Society of Urological Pathology (ISUP) grade and non-organ-confined disease (p < 0.01). The presence of lymphovascular invasion significantly increased the likelihood of pathological node-positive disease on multivariable logistic regression analysis (OR 15, 95%CI 9.7-23.6). The presence of lymphovascular invasion at radical prostatectomy significantly increased the risk of biochemical recurrence (HR 2.0, 95%CI 1.6-2.4). Furthermore, lymphovascular invasion significantly increased the risk of metastasis in the whole cohort (HR 2.2, 95%CI 1.6-3.0). The same relationship was seen across D'Amico risk groups. The presence of lymphovascular invasion at the time of radical prostatectomy is associated with aggressive prostate cancer disease features and is an indicator of poor oncological prognosis.
Cancers. 2023 Dec 26*** epublish ***
Niranjan J Sathianathen, Marc A Furrer, Clancy J Mulholland, Andreas Katsios, Christopher Soliman, Nathan Lawrentschuk, Justin S Peters, Homi Zargar, Anthony J Costello, Christopher M Hovens, Conrad Bishop, Ranjit Rao, Raymond Tong, Daniel Steiner, Daniel Moon, Benjamin C Thomas, Philip Dundee, Jose Antonio Rodriguez Calero, George N Thalmann, Niall M Corcoran
Department of Urology, The Royal Melbourne Hospital, The University of Melbourne, Melbourne, VIC 3050, Australia., Department of Urology, University of Bern, 3010 Bern, Switzerland., Epworth Healthcare, Melbourne, VIC 3121, Australia., Institute of Pathology, University of Bern, 3010 Bern, Switzerland.